リコンビナント
RabMAb

Anti-DNA PKcs (phospho S2056) 抗体 [EPR5670] (ab124918)

ab124918 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab124918 は 9 報の論文で使用されています。

  • Bian X  et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351 (2018). WB ; Human . PubMed: 28945226
  • Ando K  et al. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget 8:43733-43751 (2017). ICC/IF ; Mouse . PubMed: 28415827
  • Speers C  et al. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. NPJ Breast Cancer 3:29 (2017). PubMed: 28840192
  • Zhang H  et al. CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma. Cell Death Dis 8:e2790 (2017). PubMed: 28518141
  • Mori E  et al. Lysines 3241 and 3260 of DNA-PKcs are important for genomic stability and radioresistance. Biochem Biophys Res Commun 477:235-40 (2016). PubMed: 27297111
  • Lohse I  et al. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. PLoS One 11:e0167272 (2016). PubMed: 28033382
  • Hollingworth R  et al. Activation of DNA Damage Response Pathways during Lytic Replication of KSHV. Viruses 7:2908-27 (2015). IF . PubMed: 26057167
  • Sowd GA  et al. SV40 utilizes ATM kinase activity to prevent non-homologous end joining of broken viral DNA replication products. PLoS Pathog 10:e1004536 (2014). PubMed: 25474690
  • Juvekar A  et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2:1048-63 (2012). WB ; Human . PubMed: 22915751

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録